------------------------ Yahoo! Groups Sponsor --------------------~-->
Get fast access to your favorite Yahoo! Groups. Make Yahoo! your home page
http://us.click.yahoo.com/dpRU5A/wUILAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

Nanogen Releases Two Products for the Detection of Respiratory Viral
Pathogens

SAN DIEGO, Dec. 12 -- Nanogen, Inc. (Nasdaq: NGEN - News),
developer of advanced diagnostic products, announced today it has
expanded its molecular reagent product portfolio to include two new
products to detect sequences for respiratory viral pathogens: a
multiplex solid-phase hybridization set of reagents that can be
employed to develop and validate assays for the detection of the
sequences of six human respiratory viruses prevalent during flu
season, and a research-use-only (RUO) real-time PCR probe and primer
set for the identification of the influenza A and B viruses.

The NGEN(TM) RVA analyte specific reagent (ASR) product can be used
to develop and validate assays to detect the sequences of and
differentiates among influenza A and B, respiratory syncytial virus
and parainfluenza 1, 2 and 3. Assays validated using NGEN(TM) RVA
ASR can be carried out with various sample types, including nasal
swabs and, once validated by the laboratory, can be used as a
clinical diagnostic test. The product was developed in cooperation
with Prodesse, Inc., a leading supplier of molecular-based reagents
for infectious disease targets, and is available in the United
States as an ASR for which analytical and performance
characteristics are not established. The product has been CE marked
in the European Union as an in vitro diagnostic and is available
outside the United States.

Additionally, Nanogen has expanded its real-time PCR product group
with an RUO probe and primer set for the identification of the
influenza A and B viruses. The MGB Eclipse® Flu A/B RUO product uses
the company's proprietary MGB(TM) technology to provide melt curve
analysis that differentiates the two viral strains for each sample.
The new MGB Eclipse® Flu A/B primer and probe set, along with the
recently released Enterovirus and hMPV reagents, complement
Nanogen's growing MGB Alert(TM) product family of ASRs targeting
infectious agents, such as herpes viruses and pneumonias.

Both sets and reagents target a nucleic acid sequence also found in
the H5N1 strain of the influenza A virus, also known as avian flu.
Laboratories interested in screening for avian flu can choose
between the real-time PCR research reagents or the set of ASRs that
can be validated for clinical use. Positives could then be sequenced
for epidemiological studies.

"The market for respiratory virus testing is estimated to be over
$100 million annually. With the shipment of these new products,
Nanogen is making a strong play to grab a piece of that market,"
noted Howard C. Birndorf, chairman and chief executive officer of
Nanogen. "Traditionally, labs testing for flu have been limited to
choosing between simple rapid tests, which often lack sensitivity
and specificity, or culture-based tests that are slow to get
results. Our advanced molecular-based technologies offer clinical
and research labs additional options. We believe our products will
enable changes in laboratory procedures that can influence better
prescribing practices and improve patient care."

About Nanogen, Inc.

Nanogen's advanced technologies provide researchers, clinicians and
physicians worldwide with improved methods and tools to predict,
diagnose, and ultimately help treat disease. The company's products
include real-time PCR reagents, the NanoChip® electronic microarray
platform and a line of reagents useful in rapid diagnostic tests.
Nanogen's ten years of pioneering research involving nanotechnology
holds the promise of miniaturization and continues to be supported
for its potential for diagnostic and biowarfare applications. For
additional information please visit Nanogen's website at
www.nanogen.com.

Forward-Looking Statement

This press release contains forward-looking statements that are
subject to risks and uncertainties that could cause actual results
to differ materially from those set forth in the forward-looking
statements, including whether products under development can be
successfully developed and commercialized, whether patents owned or
licensed by Nanogen will be developed into products, whether the
patents owned by Nanogen offer any protection against competitors
with competing technologies, whether results reported by our
customers or partners can be identically replicated, and other risks
and uncertainties discussed under the caption "Factors That May
Affect Results" and elsewhere in Nanogen's Form 10-K or Form 10-Q
most recently filed with the Securities and Exchange Commission.
These forward-looking statements speak only as of the date hereof.
Nanogen disclaims any intent or obligation to update these forward-
looking statements.

---------------------------------------------------------------------
-----------
Source: Nanogen, Inc.

http://groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/
http://www.imhcaz.com/
http://www.azhttp.com/

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech